Cystatin C

There are 580 papers on cystatin C in aging research: 28 trials and 477 observational studies in people, 22 in animals, 41 reviews. The newest story, Nov 14, 2026: “Kidney test mismatch linked to death risk in older adults”.

Biomarker

580 papers study it135 more mention it131 findings

MeSH

41 new papers in 30 daysSee all 715 papers on cystatin C

“associations between changes in physical function and PA or SB with some of the selected biomarkers, namely TNF-alpha, troponins and most convincingly in cystatin C”
Association between changes in physical performance and changes in biomarkers during a physical activity intervention in older adults - an exploratory studyExperimental gerontology2025doi:10.1016/j.exger.2025.112959
  • Human trial28
  • Humans477
  • Animals22
  • In silico7

Interventions

8

Caloric restriction

downin humans1no changein rats1

2 studies
  1. Caloric restriction decreases cystatin C in humans (older adults with obesity; compared with weight stability) (WL: -2.53 ng/mL versus WS: 0.07 ng/mL; p = .04).

    “only Cystatin-C significantly changed (WL: -2.53 [95% CI: -4.38, -0.68] ng/mL vs WS: 0.07 [95% CI: -1.85, 1.98] ng/mL; p = .04)”

    Human trialolder adults with obesity; compared with weight stability6 months

    Effect of Intentional Weight Loss on Mortality Biomarkers in Older Adults With Obesity

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Caloric restriction showed no clear effect on cystatin C in rats.

    “Interestingly, cystatin C levels were not corrected by caloric restriction.”

    Animalsplasmamales

    Structural equation modeling identifies markers of damage and function in the aging male Fischer 344 rat

    Mechanisms of ageing and development

More on Caloric restriction

High-salt diet

upin rats1

1 study
  1. High-salt diet increases cystatin C in rats.

    “Urinary cystatin C increased significantly in females but not in males following high-salt exposure.”

    Animalsfemales

    Sex differences in the progression of salt-sensitive hypertension in aged Dahl salt-sensitive rats

    American journal of physiology. Regulatory, integrative and comparative physiology

More on High-salt diet

Volunteering

downin humans1

1 study
  1. Volunteering is linked with lower cystatin C in humans (sustained volunteering vs no volunteering) (-3.7% (-0.08, p < 0.001)).

    “a 3.7% lower prevalence of unhealthy Cystatin C levels (-0.08, p < 0.001)”

    Humanssustained volunteering vs no volunteering

    Volunteering and Cardiovascular Biomarkers: A Machine-Learning Causal Approach in Health and Retirement Study

    GSA 2025 abstract

More on Volunteering

Alcohol dependence treatment program

downin humans1

1 study
  1. Alcohol dependence treatment program is linked with lower cystatin C in humans (measured before and after the treatment program in patients with alcohol dependence).

    “beta-2-microglobulin and Cystatin C decreased after the treatment program than before”

    Humansmeasured before and after the treatment program in patients with alcohol dependence

    Accelerated epigenetic aging in alcohol dependence

    Journal of psychiatric research

More on Alcohol dependence treatment program

Antiretroviral therapy

no changein humans1

1 study
  1. Antiretroviral therapy showed no clear effect on cystatin C in PLWH on ART.

    “serum levels of cystatin C remained unchanged or were not affected in PLWH on ART”

    Reviewin PLWH on ART

    A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy

    Frontiers in medicine

More on Antiretroviral therapy

Sitagliptin

upin humans1

1 study
  1. Sitagliptin increases cystatin C in humans (versus control without sitagliptin).

    “except for cystatin C elevation and platelet count reduction in sitagliptin group”

    Human trialversus control without sitagliptin12 months

    Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

    Scientific reports

More on Sitagliptin

Treadmill exercise

downin rats1

1 study
  1. Treadmill exercise decreases cystatin C in rats.

    “Also, it revealed that treadmill exercise alleviated theses effects in exercised aged group with reduction of urea and cystatin C.”

    Animalsmoderate-intensitykidney8 weeksmales

    Treadmill Exercise Training Ameliorates Functional and Structural Age-Associated Kidney Changes in Male Albino Rats

    TheScientificWorldJournal

More on Treadmill exercise

Berberine

downin humans1

1 study
  1. Berberine decreases cystatin C in humans (type 2 diabetes mellitus) ((0.83±0.30) mg/L vs (0.96±0.30)mg/L, P=0.041).

    “berberine administration was independently associated with the reduction of UACR (β=-0.051, P=0.041) and Cys C (β=-0.068, P=0.033) in T2DM patients.”

    Human trialtype 2 diabetes mellitus0.4 g, 3 times a daysix monthsn = 114

    Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus

    Zhonghua yi xue za zhi

More on Berberine

Effects

13

Kidney failure

mediatesin humans1

1 study
  1. Cystatin C is linked with kidney failure in humans (Mediation of the relationship between body mass index and renal failure) (12.34% mediated).

    “five acted as mediators in the relationship between BMI and renal failure: cystatin C (12.34%), glucose (7.02%), glycated hemoglobin (HbA1c) (6.83%), diastolic blood pressure (6.37%)”

    HumansMediation of the relationship between body mass index and renal failure

    A Mendelian randomization analysis of the causal effect of body mass index on biomarkers and renal failure risk

    Medicine

More on Kidney failure

Frailty index

mediatesin humans1

1 study
  1. Cystatin C is linked with frailty index in humans (persistent hypertension-FI association).

    “Exploratory mediation analyses suggested that cystatin C and C-reactive protein partly mediated the persistent hypertension-FI association.”

    Humanspersistent hypertension-FI associationn = 6,770

    Hypertension Trajectories and Frailty Among Middle-Aged and Older Chinese Adults: A CHARLS Cohort Study

    Geriatrics & gerontology international

More on Frailty index

Bone mineral density

mediatesin humans1

1 study
  1. Cystatin C is linked with bone mineral density in humans (DBP-dependent).

    “renal biomarker cystatin C and endocrine biomarker IGF-1 exhibited DBP-dependent associations with BMD, mediating the nonlinear DBP-bone density relationship”

    HumansDBP-dependent

    Dissecting the comprehensive relationship between blood pressure and bone mass: the observational association and pleiotropic drug targets

    medRxivPreprint

GFR estimation accuracy

upin reviews1

1 study
  1. Cystatin C improves GFR estimation accuracy (CKD diagnosis and staging).

    “Cystatin C-inclusive equations generally outperform creatinine-based equations in bias and accuracy across diverse populations, including children and patients with comorbidities.”

    ReviewCKD diagnosis and staging

    Use of Cystatin C in Tandem with Creatinine to Improve GFR Estimation and Clinical Decision Making

    Journal of the American Society of Nephrology : JASN

Early CKD detection

upin humans1

1 study
  1. Cystatin C improves early CKD detection in humans (combined creatinine - cystatin C or cystatin C based eGFR equations).

    “Cystatin C based and combined creatinine - cystatin C eGFR equations demonstrate improved accuracy for detecting early CKD”

    Reviewcombined creatinine - cystatin C or cystatin C based eGFR equations

    Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes

    Postgraduate medicine

Cognitive impairment

no changein humans1

1 study
  1. Cystatin C was not clearly linked with cognitive impairment in humans with albuminuria (OR per SD 1.00, 95% CI 0.73-1.25).

    “absent in those with albuminuria (OR per SD = 1.00, 95% CI: 0.73-1.25, p = 0.981)”

    Humanswith albuminuria

    Serum cystatin C and cognitive function in midlife: results from the Hanzhong Adolescent Hypertension Study

    Frontiers in neurology

More on Cognitive impairment

Major adverse kidney events

no changein humans1OR 0.94

1 study
  1. Cystatin C was not clearly linked with major adverse kidney events in humans (independent of eGFR, albuminuria and CKD risk factors) (OR 0.94 (95% CI 0.74-1.19)).

    “No significant association was observed for urine CysC (OR: 0.94, 95% CI: 0.74-1.19).”

    Humansindependent of eGFR, albuminuria and CKD risk factorsurine13 years of follow-up

    Proximal Tubule Reabsorption and CKD Progression in the General Population

    Kidney international reports

Atherosclerosis

mediatesin humans1

1 study
  1. Cystatin C is linked with atherosclerosis in humans (8.22% mediated).

    “Mediation analysis revealed that cystatin C partially mediated (8.22%) the effect of ANGPTL8 on atherosclerosis, whereas triglycerides showed negligible mediation.”

    HumansPartial mediation of the ANGPTL8–atherosclerosis association in patients with type 2 diabetesn = 202

    Elevated ANGPTL8 (Angiopoietin-Like Protein 8) Levels as a Novel Predictor of Atherosclerosis in Type 2 Diabetes: Beyond Lipid Metabolism

    Journal of the American Heart Association

More on Atherosclerosis

Kidney failure risk model performance

no changein humans1

1 study
  1. Cystatin C was not clearly linked with kidney failure risk model performance in humans (compared with creatinine-based eGFR in KFRE).

    “Using cystatin C compared to creatinine did not improve model performance.”

    Humanscompared with creatinine-based eGFR in KFRE

    Accounting for death improved kidney failure risk predictions

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Muscle mass

no changein humans1

1 study
  1. Cystatin C was not clearly linked with muscle mass in humans (unadjusted for creatinine).

    “serum cystatin C was not associated with muscle mass.”

    Humansunadjusted for creatinine

    Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population-based cohort

    Journal of cachexia, sarcopenia and muscle

All 13

Upstream

3

Age

upin humans1

1 study
  1. Age is linked with higher cystatin C in humans.

    “Older individuals and men were more likely to have Cys C levels above the RIs”

    Humans

    Updated reference intervals for serum cystatin C and creatinine based on age and sex variations

    Scientific reports

Chronic kidney disease

upin humans1

1 study
  1. Chronic kidney disease is linked with higher cystatin C in humans (CKD patients).

    “Serum cystatin level was significantly high in CKD patients while MMSE scores were significantly lower in CKD patients.”

    HumansCKD patientsn = 90

    Association of Serum Levels of Cystatin C and Cognition in a Cohort of Egyptian Elderly Patients with Chronic Kidney Disease

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

More on Chronic kidney disease

Older age

upin humans1

1 study
  1. older age is linked with higher cystatin C in humans.

    “expression of the four indexes was up-regulated in the elderly population compared with those in the younger population”

    Humanskidney

    Analysis of renal function in a Health Examination Population in Chengdu (2012-2018)

    Preprint

Associations

60

Mortality

upin humans17upin dogs1upin reviews1HR 1.2–9.66

19 studies
  1. Cystatin C predicts mortality in humans (fully adjusted models) (HR 1.76, 95% CI 1.36-2.28).

    “cystatin C (HR = 1.76; 1.36-2.28), β2-microglobulin (HR = 1.72; 1.36-2.16), and UACR (HR = 1.50; 1.23-1.81) were significantly associated with all-cause mortality”

    Humansfully adjusted modelsn = 4,087

    Comparative prognostic value of nine cardiorenal biomarkers for mortality among adults with prediabetes and diabetes

    Diabetes, obesity & metabolism

  2. Cystatin C is associated with mortality in humans (sarcopenia).

    “Hs-CRP and CysC were prominently associated with all-cause mortality as continuous variables.”

    Humanssarcopenian = 612

    Association between high-sensitivity C-reactive protein, cystatin C and all-cause mortality in middle-aged and elderly participants with sarcopenia

    Aging clinical and experimental research

  3. Cystatin C predicts mortality in patients with angiographically verified coronary artery disease (standardized adjusted HR 1.20 [1.13-1.28], p<0.001).

    “Cystatin C proved to be a strong and independent predictor for mortality in the total study cohort (standardized adjusted HR 1.20 [1.13-1.28], p<0.001).”

    Humansin patients with angiographically verified coronary artery disease11.5±5.0 yearsn = 1,115

    Cystatin C Predicts Mortality in Patients with Coronary Artery Disease Both among Subjects with and among Those without the Metabolic Syndrome

    ADA Scientific Sessions 2025 abstract

  4. Cystatin C predicts mortality in humans (C-index from 0.745 to 0.839, AUC from 0.751 to 0.845).

    “The predictive performance significantly improves by including longitudinal changes in Cystatin C in baseline-only models, with the concordance index increasing from 0.745 to 0.839 and the area under the receiver operator characteristic curve rising from 0.751 to 0.845.”

    Humansplasman = 3,195

    Longitudinal changes in plasma Cystatin C and all-cause mortality risk among the middle-aged and elderly Chinese population

    Clinical biochemistry

  5. Cystatin C is linked with a higher risk of mortality in humans (HR: 1.51, 95 % CI: 1.02-2.24, p = 0.04).

    “Participants in the highest quartile of baseline Cystatin C show an increased risk of mortality compared to those in the lowest quartile (hazard ratio (HR): 1.51, 95 % CI: 1.02-2.24, p = 0.04).”

    Humansplasman = 3,195

    Longitudinal changes in plasma Cystatin C and all-cause mortality risk among the middle-aged and elderly Chinese population

    Clinical biochemistry

  6. Cystatin C is linked with a higher risk of mortality in humans (participants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)) (HR: 2.71, 95% CI: 2.17-3.38).

    “HR: 2.71, 95% CI: 2.17-3.38, P < 0.001; respectively”

    Humansparticipants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)15.62 ± 4.68 yearsn = 9,894

    Cystatin C and sarcopenia index are associated with cardiovascular and all-cause death among adults in the United States

    BMC public health

  7. Cystatin C is associated with mortality in humans (adjusted for creatinine).

    “while the association between serum cystatin C and increased mortality strengthened.”

    Humansadjusted for creatinine

    Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population-based cohort

    Journal of cachexia, sarcopenia and muscle

  8. Cystatin C is associated with mortality in humans (hip fracture) (HR 2.19, 95 % CI: 1.72-2.79, P < 0.0001).

    “Linear multivariate Cox regression analysis revealed a significant association between preoperative cystatin C level and death, with a hazard ratio (HR) of 2.19 (95 % confidence interval [CI]: 1.72-2.79, P < 0.0001).”

    Humanship fractureserum37.62 months

    Serum cystatin C as a biomarker to predict all-cause mortality in geriatrics hip fracture

    Heliyon

  9. Cystatin C is linked with a higher risk of mortality in humans (HR 1.92, 95% CI 1.62-2.28).

    “hazard ratios and 95% confidence intervals were 1.92 (1.62-2.28) for all-cause mortality”

    Humansn = 13,913

    Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study

    Scientific reports

  10. Cystatin C is associated with mortality in humans (+28% to +31% relative risk per 10% increase).

    “A 10% increase in Cystatin-C was highly associated with increased relative risk of death (28% and 31% by years 4 and 8).”

    Humans8-yearsn = 7,027

    Serum Cystatin-C is linked to increased prevalence of diabetes and higher risk of mortality in diverse middle-aged and older adults

    PloS one

All 20

Frailty

upin humans8mixedin silico1HR 2.05

9 studies
  1. Cystatin C is linked with a higher risk of frailty in humans (normal eGFRscr in HRS cohort) (HR 2.05 (95% CI 1.30-3.22) per 1-unit increase).

    “For each 1-unit increase in cystatin C, the adjusted hazard ratios (HRs) were 2.05 (95% CI: 1.30-3.22) in HRS”

    Humansnormal eGFRscr in HRS cohort

    Higher cystatin C, but not creatinine, predicts frailty risk in individuals with normal kidney function

    The Journal of frailty & aging

  2. Cystatin C is associated with frailty in humans (chronic kidney disease) (adjusted OR 52.46, 95%CrI 9.51-356.12).

    “Elevated cystatin C levels showed a strong positive association (adjusted OR 52.46, 95%CrI 9.51-356.12)”

    Humanschronic kidney disease

    Bayesian Analysis of Frailty Risk Factors in Chronic Kidney Disease: A Nationwide Cross-Sectional Survey

    Health science reports

  3. Cystatin C predicts frailty in humans.

    “subsequent SHAP analysis demonstrated that only cystatin C was the primary contributor in both models”

    Humansn = 9,702

    Explainable machine learning framework for biomarker discovery by combining biological age and frailty prediction

    Scientific reports

  4. Cystatin C is associated with frailty in humans (adjusted for BMI, age, sex, and smoking) (0.004, 95% CI: 0.002, 0.006, p < 0.01).

    “cystatin C: 0.004, 95% CI: 0.002, 0.006”

    Humansadjusted for BMI, age, sex, and smokingbloodn = 403

    Inflammatory markers and frailty in home-dwelling elderly, a cross-sectional study

    BMC geriatrics

  5. Cystatin C is associated with frailty in humans (β = 0.050 SD/y, 95% CI, 0.045-0.055 SD/y).

    “Each SD increment in serum cystatin C was associated with a faster increase in FI in both the HRS cohort (β = 0.050 SD/y; 95% CI, 0.045-0.055 SD/y; P = .001)”

    Humansn = 9,114

    Association of Cystatin C Kidney Function Measures With Long-term Deficit-Accumulation Frailty Trajectories and Physical Function Decline

    JAMA network open

  6. Cystatin C is associated with frailty in humans (community-dwelling adults in China) (OR 4.5, 95% CI 3.0–6.7).

    “Relative factors for frailty also included increased cystatin C (OR: 4.5, 95% CI: 3.0, 6.7)”

    Humanscommunity-dwelling adults in Chinan = 9,985

    A cross-sectional survey of prevalence and related factors for frail status among middle-aged and elderly people in Chinese communities

    Research SquarePreprint

  7. Cystatin C is associated with frailty in humans (without renal dysfunction) (2.52 (1.05-6.02) times the risk of being frail).

    “Multivariate analysis showed that higher cystatin C level was associated with 2.52 (1.05-6.02) times the risk of being frail.”

    Humanswithout renal dysfunctionserumn = 125

    Raised serum cystatin C can be a potential biomarker of frailty detected by cumulative deficit model

    Aging medicine (Milton (N.S.W))

  8. Cystatin C is associated with frailty in humans (OR 3.13, 95% CI 2.03–4.82, quartile 4 versus 1; frail versus robust).

    “a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82)”

    HumansWithout overt frailty at baseline; highest versus lowest cystatin C quartile; adjusted for age, clinical site, and raceAverage of 3.4 yearsmalesn = 2,613

    Cystatin C and the Risk of Frailty and Mortality in Older Men

    The journals of gerontology. Series A, Biological sciences and medical sciences

  9. Cystatin C predicts frailty in silico (SHAP analysis of prediction models in Chinese adults).

    “However, subsequent SHAP analysis demonstrated that only cystatin C was the primary contributor in both models”

    In silicoSHAP analysis of prediction models in Chinese adults

    Explainable machine learning framework for biomarker discovery by combining biological age and frailty prediction (Preprint)

    Preprint

Stroke

upin humans5OR 1.38

5 studies
  1. Cystatin C is linked with a higher risk of stroke in both males and females.

    “High DBP, systolic blood pressure, total metabolic output, and Cystatin C in both males and females were still significantly associated with the risk of stroke (P < .05).”

    Humansin both males and females

    Analysis of sex-specific stroke risk factors in middle-aged and elderly Chinese population based on machine learning approach: A retrospective observational cohort study

    Medicine

  2. Cystatin C is linked with a higher risk of stroke in humans after adjusting for confounding factors, highest vs lowest quartile (OR 1.380, 95% CI 1.046-1.825).

    “those in the last quartile had the greatest risk of stroke incidence [odds ratio (OR), 1.380; 95% confidence interval (CI), 1.046-1.825]”

    Humansafter adjusting for confounding factors, highest vs lowest quartile

    Serum cystatin C and stroke risk: a national cohort and Mendelian randomization study

    Frontiers in endocrinology

  3. Cystatin C predicts stroke in humans (obstructive sleep apnea) (AUC 0.731, 95% CI 0.683-0.779).

    “capability of Cys-C to identify elderly patients with OSA who had a long-time risk of stroke was moderate (AUC = 0.731, 95% CI: 0.683-0.779, P = 0.001).”

    Humansobstructive sleep apneaserumn = 932

    Association Cystatin C and Risk of Stroke in Elderly Patients With Obstructive Sleep Apnea: A Prospective Cohort Study

    Frontiers in neuroscience

  4. Cystatin C is linked with a higher risk of stroke in humans (obstructive sleep apnea) (HR 2.16, 95% CI 1.09-6.60).

    “patients with a serum Cys-C concentration of ≥1.15 mg/L had a 2.16-fold higher risk of developing stroke compared with patients with serum Cys-C ≤ 0.81 mg/L”

    Humansobstructive sleep apneaserum≥1.15 mg/L vs ≤0.81 mg/Lmedian 42-monthn = 932

    Association Cystatin C and Risk of Stroke in Elderly Patients With Obstructive Sleep Apnea: A Prospective Cohort Study

    Frontiers in neuroscience

  5. Cystatin C is linked with a higher risk of stroke in humans (hazard ratio, 1.47 [ 1.09 to 1.96]).

    “stroke (hazard ratio, 1.47 [ 1.09 to 1.96]) after multivariate adjustment”

    Humans> or =1.29 mg per litern = 4,637

    Cystatin C and the risk of death and cardiovascular events among elderly persons

    The New England journal of medicine

  6. Cystatin C predicts stroke in humans (without a history of cerebrovascular) (HR 1.18, 95% CI 1.04-1.31).

    “the hazard ratio for all types of stroke, including ischemic and hemorrhagic stroke, was 1.18 (95% confidence interval 1.04-1.31)”

    Reviewwithout a history of cerebrovascularn = 26,768

    Cystatin C predicts the risk of incident cerebrovascular disease in the elderly: A meta-analysis on survival date studies

    Medicine

More on Stroke

Cardiovascular mortality

upin humans3HR 1.18–3.36

3 studies
  1. Cystatin C is linked with a higher risk of cardiovascular mortality in humans (participants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)) (HR: 3.36, 95% CI: 2.06-5.46).

    “the risk of cardiovascular and all-cause death increased 2.36-fold and 1.71-fold for participants in the fourth quartile (≥ 0.877 mg/L) (HR: 3.36, 95% CI: 2.06-5.46, P < 0.001”

    Humansparticipants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)15.62 ± 4.68 yearsn = 9,894

    Cystatin C and sarcopenia index are associated with cardiovascular and all-cause death among adults in the United States

    BMC public health

  2. Cystatin C is linked with a higher risk of cardiovascular mortality in humans (HR 1.98, 95% CI 1.48-2.65).

    “1.98 (1.48-2.65) for cardiovascular mortality”

    Humansn = 13,913

    Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study

    Scientific reports

  3. Cystatin C predicts cardiovascular mortality in humans (Age-adjusted analysis; per 0.1-unit increase) (HR 1.18 (95% CI 1.09–1.28) per 0.1-unit increase).

    “cystatin C predicted the risk of non-cardiovascular and cardiovascular death in men”

    HumansAge-adjusted analysis; per 0.1-unit increase9 yearsmales

    Biomarkers of kidney function and prediction of death from cardiovascular and other causes in the elderly: A 9-year follow-up study

    European journal of internal medicine

Telomere length

downin humans2mixedin humans1

3 studies
  1. Telomere length is associated with cystatin C in humans (healthy people).

    “Interestingly, telomere length was strongly correlated only with the renal indicators eGFR (P < .001), CYS-C (P < .001), and SCR (P < .001).”

    Humanshealthy peoplen = 632

    Objective assessment of the association between telomere length, a biomarker of aging, and health screening indicators: A cross-sectional study

    Medicine

  2. Cystatin C is associated with telomere length in humans (unadjusted association in healthy Han Chinese volunteers) (r = -0.180).

    “Leukocyte TRF lengths were negatively correlated to age (r = -0.393, p < 0.001) and serum CysC (r = -0.180, p < 0.01)”

    Humansunadjusted association in healthy Han Chinese volunteersperipheral blood leukocyte

    Peripheral Blood Leukocyte Telomere Length Is Associated with Age but Not Renal Function: A Cross-Sectional Follow-Up Study

    The journal of nutrition, health & aging

  3. Cystatin C is associated with telomere length in humans (adjusted for immune cell type distributions) (-0.0391 kilobase pairs per unit; 95% CI -0.0772 to -0.00107).

    “cystatin C -0.0391 (95% CI -0.0772--0.00107)”

    Humansadjusted for immune cell type distributionsleukocyten = 7,252

    Leukocyte Telomere Length in Relation to 17 Biomarkers of Cardiovascular Disease Risk: A Cross-Sectional Study of US Adults

    PLoS medicine

More on Telomere length

Major adverse cardiovascular events

upin humans2

2 studies
  1. Cystatin C is associated with major adverse cardiovascular events in humans (CKM stages 0–3).

    “elevated FLI, CysC, and hsCRP were independently associated with MACE across all CKM stages.”

    HumansCKM stages 0–3Median follow-up of 15.2 yearsn = 382,797

    Aggregate risk score based on markers of hepatic steatosis, systemic inflammation, and renal stress to predict MACE across the CKM spectrum

    ESC Congress 2026 abstract

  2. Cystatin C is associated with major adverse cardiovascular events in humans (Placebo-treated patients with type 2 diabetes; fourth versus first quartile).

    “higher baseline CysC was associated with higher risk for CVD/HHF, MACE, and the kidney-specific composite outcome.”

    HumansPlacebo-treated patients with type 2 diabetes; fourth versus first quartilen = 1,899

    Comparative risk assessment of cardiovascular and kidney outcomes in patients with type 2 diabetes using cystatin C and creatinine in DECLARE-TIMI 58

    American heart journal plus : cardiology research and practice

Cardiovascular disease

mixedin humans1upin humans1

2 studies
  1. Cardiovascular disease is associated with cystatin C in humans (cross-lagged path analysis).

    “The bidirectional CVD-TyG-BMI relationship and unidirectional CVD-cystatin C association suggest comorbidity risks between cardiovascular, metabolic, and renal diseases.”

    Humanscross-lagged path analysis

    Identification of Core Biomarkers and Temporal Mechanism Investigation in Cardiovascular Disease: A Machine Learning and Cross-Lagged Path Model Approach

    Research SquarePreprint

  2. Cystatin C is associated with cardiovascular disease in humans (SHAP interpretability analysis of machine learning models).

    “SHAP analysis identified age, HbA1c, UA, and Cys C as variables increasing the predicted risk of CVDs”

    HumansSHAP interpretability analysis of machine learning modelsn = 10,657

    Association of frailty-risk indicators with cardiovascular diseases: evidence from the CHARLS

    BMC cardiovascular disorders

More on Cardiovascular disease

Cognitive decline

upin humans2OR 1.585

2 studies
  1. Cystatin C is linked with a higher risk of cognitive decline in humans (β=0.461, OR=1.585, 95% CI: 1.154-2.177, P < 0.05).

    “Cystatin C (CysC; β=0.461, OR=1.585, 95% CI: 1.154-2.177, P < 0.05)”

    Humans10 yearsn = 6,810

    Comparison of cognitive decline rates and risk factors between stroke and non - stroke populations: An analysis of data from the China health and retirement longitudinal study (CHARLS)

    Cerebral circulation - cognition and behavior

  2. Cystatin C is linked with a higher risk of cognitive decline in non-diabetic individuals.

    “In the non-DM (non-diabetes mellitus) group, cumulative Cystatin C increased the risk of cognitive decline.”

    Humansin non-diabetic individuals

    Long-term cystatin C trajectories and cognitive decline in diabetes and non-diabetes: evidence from a national Chinese cohort

    Frontiers in medicine

Cognitive impairment

upin humans2OR 1.49

2 studies
  1. Cystatin C is linked with a higher risk of cognitive impairment in humans (fully adjusted) (OR 1.49, 95% CI 1.24-1.79).

    “Each 1-SD increase in CysC levels was significantly associated with 49% higher odds of cognitive impairment after full adjustment [odds ratio (OR) = 1.49, 95% confidence interval (CI): 1.24-1.79, p < 0.001].”

    Humansfully adjustedn = 1,929

    Serum cystatin C and cognitive function in midlife: results from the Hanzhong Adolescent Hypertension Study

    Frontiers in neurology

  2. Cystatin C is associated with cognitive impairment in humans.

    “the levels of serum cystatin C and urinary albumin were found being significantly associated with cognitive impairment”

    Humans

    Early markers of kidney dysfunction and cognitive impairment among older adults

    Journal of the neurological sciences

More on Cognitive impairment

Biological age

upin humans1mixedin silico1

2 studies
  1. Cystatin C predicts biological age in humans.

    “subsequent SHAP analysis demonstrated that only cystatin C was the primary contributor in both models”

    Humansn = 9,702

    Explainable machine learning framework for biomarker discovery by combining biological age and frailty prediction

    Scientific reports

  2. Cystatin C predicts biological age in silico (SHAP analysis of prediction models in Chinese adults).

    “However, subsequent SHAP analysis demonstrated that only cystatin C was the primary contributor in both models”

    In silicoSHAP analysis of prediction models in Chinese adults

    Explainable machine learning framework for biomarker discovery by combining biological age and frailty prediction (Preprint)

    Preprint

More on Biological age

Contrast-associated acute kidney injury detection

upin humans1

1 study
  1. Cystatin C is associated with contrast-associated acute kidney injury detection in humans (7 cystatin C-defined cases versus 4 creatinine-defined events; no overlapping cases; κ = 0.07).

    “Creatinine-based criteria identified 4 CA-AKI events, whereas cystatin C identified 7 additional early functional injury cases.”

    Human trialPatients with peripheral arterial disease undergoing elective intra-arterial contrast-enhanced vascular procedures; comparison with creatinine-based criterian = 76

    Biomarker-dependent detection of contrast-associated acute kidney injury after intra-arterial contrast procedures: an exploratory randomized trial

    BMC nephrology

Waist circumference

upin humans1

1 study
  1. Cystatin C predicts waist circumference in humans (β = 0.500).

    “In addition, Δcystatin C (β = 0.500) was considered an independent explanatory variable for the change in waist circumference (Δwaist circumference).”

    Human trial6-monthfemalesn = 33

    Weight Loss Intervention and Early Biomarker Search in Middle-Aged and Elderly Women: Early Signs of Body Composition Changes Indicated by Blood Cholinesterase and Cystatin C

    Journal of Endocrinology and Metabolism

Physical function and physical activity changes

mixedin humans1

1 study
  1. Cystatin C is associated with physical function and physical activity changes in humans (changes over a 16-week physical activity intervention).

    “associations between changes in physical function and PA or SB with some of the selected biomarkers, namely TNF-alpha, troponins and most convincingly in cystatin C”

    Human trialchanges over a 16-week physical activity intervention16 weeksn = 339

    Association between changes in physical performance and changes in biomarkers during a physical activity intervention in older adults - an exploratory study

    Experimental gerontology

All 60

Funding

1 grant since 2021

National Institute of Diabetes and Digestive and Kidney Diseases$951K

Latest

Dec 2025: 20Jan 2026: 23Feb 2026: 30Mar 2026: 24Apr 2026: 7May 2026: 7Jun 2026: 6Jul 2026: 21Aug 2026: 22Sep 2026: 20Oct 2026: 33Nov 2026: 15228 papers in 12 months
BMC Geriatrics

Kidney test mismatch linked to death risk in older adults

Low versus preserved kidney function on a second test was linked to higher death risk, with hazard ratios of 1.44 and 1.62.Low versus preserved kidney function on a second test was linked to higher death risk, with hazard ratios of 1.44 and 1.62.

Cohort · 8,384 peopleBiomarkers

See all 715 papers on cystatin C